



US 20130315916A1

(19) **United States**

(12) **Patent Application Publication**
Saelens et al.

(10) **Pub. No.: US 2013/0315916 A1**

(43) **Pub. Date: Nov. 28, 2013**

(54) **RESPIRATORY SYNCYTIAL VIRUS VACCINE**

Publication Classification

(75) Inventors: **Xavier Saelens**, Ieper (BE); **Bert Schepens**, Gent (BE); **Walter Fiers**, Destelbergen (BE)

(51) **Int. Cl.**
C07K 16/10 (2006.01)
C07K 14/78 (2006.01)
C07K 7/06 (2006.01)
C07K 14/005 (2006.01)

(73) Assignees: **Universiteit Gent**, Gent (BE); **VIB VZW**, Gent (BE)

(52) **U.S. Cl.**
CPC **C07K 16/1027** (2013.01); **C07K 14/005** (2013.01); **C07K 14/78** (2013.01); **C07K 7/06** (2013.01)

(21) Appl. No.: **13/885,388**

USPC **424/139.1**; 424/186.1; 530/350; 530/324; 530/387.9; 436/501

(22) PCT Filed: **Nov. 15, 2011**

(86) PCT No.: **PCT/EP2011/070161**

§ 371 (c)(1),
(2), (4) Date: **Aug. 7, 2013**

(57) **ABSTRACT**

Related U.S. Application Data

(60) Provisional application No. 61/458,012, filed on Nov. 15, 2010.

Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or a pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.

(30) **Foreign Application Priority Data**

Nov. 15, 2010 (GB) 1019240.9